Chinese Academy of Medical Sciences: Triple Negative Breast Neoplasms trials

The registry lists 11 Triple Negative Breast Neoplasms studies with Chinese Academy of Medical Sciences as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 2 8Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT04437160Phase 2
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast CancerStatus unknownNCT01928680Phase 2Results posted
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
• Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownNCT05089643Phase 2
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyStatus unknownNCT03876886Phase 3
• Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
• Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast CancerStatus unknownNCT02595138Phase 3
• The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBCStatus unknownNCT01378533Phase 3
• Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerStatus unknownNCT01276769Phase 2
• Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast CancerCompletedNCT01150513Phase 2/3